VarmX raises € 12.5 million to develop PseudoXa
Funding enables clinical stage trials of lead compound PseudoXa.
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants.
VarmX raises seed capital for development of PseudoXa
Restoring blood clotting in patients using anticoagulants.